Manufacturing – Page 3

Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges

AstraZeneca Cancels £450 Million UK Vaccine Plant Expansion Amid Government Funding Reduction

6 months ago talkbio0Tagged Administration occupational activities, AstraZeneca, Drug Industry, Economic Growth, Government, Investments, Labor (Childbirth), Manufacturing, UK, Vaccines

AstraZeneca, vaccine manufacturing, UK investment, government funding, Labour administration, economic growth, pharmaceutical industry

Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

6 months ago talkbio0Tagged Biological Factors, Biopharma, CDMO, Cells, Demand (clinical), gene therapy, Manufacturing, Market, Rentschler, Stevenage facility closure, strategic realignment

Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure

Catalent and Galapagos Collaborate on Decentralized CAR-T Manufacturing; Kindeva Secures $129M Contract for Nerve Agent Antidote

6 months ago talkbio0Tagged Antidote, CAR-T, Catalent, decentralized, Duodote, Galapagos, Kindeva, Lymphoma, Non-Hodgkin, Manufacturing, Nerve Agents, NHL, Strategic National Stockpile

Catalent, Galapagos, CAR-T therapy, Decentralized manufacturing, Non-Hodgkin lymphoma (NHL), Kindeva Drug Delivery, DuoDote, Nerve agent antidote, Strategic National Stockpile

FDA Places Clinical Hold on Atara Biotherapeutics’ EBVALLO and ATA3219 Due to Manufacturing Compliance Issues

6 months ago talkbio0Tagged allogeneic T-cell therapies, Atara Biotherapeutics, Biomechanical compliance, Ebvallo, Epstein-Barr virus, GMP, Guanosine Monophosphate, Lupus Erythematosus, Systemic, Manufacturing, Post-transplant lymphoproliferative disorder, Study on Hold, United States Food and Drug Administration

Atara Biotherapeutics, FDA clinical hold, EBVALLO, ATA3219, allogeneic T-cell therapies, manufacturing compliance issues, GMP compliance, Epstein-Barr virus, post-transplant lymphoproliferative disease, non-Hodgkin’s lymphoma, systemic lupus erythematosus.